NCPE Assessment

Plain English Summary

September, 2025

Drug name: Zanubrutinib (pronounced as zan-yoo-broo-tih-nib) for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based therapy

Brand name: Brukinsa®

HTA ID: 23072

NCPE
National Centre for Pharmacoeconomics, Ireland

What is the NCPE?

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

How do we make our recommendations?

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

What is **zanubrutinib** used for?

Zanubrutinib is a medicine for treating adults with marginal zone lymphoma (MZL), when the disease has returned after at least one prior therapy targeting a protein on B lymphocytes called CD20. MZL is a type of non-Hodgkin lymphoma, which is a cancer that develops from a type of white blood cell called B-cells.

What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should consider not funding for zanubrutinib unless its cost effectiveness (value for money) can be improved. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional criteria outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

Why did we make this recommendation?

After reviewing the data presented by the pharmaceutical company, we concluded that the medicine may work as well or better than other ways to manage this condition. However, the price of the medicine is too high compared with other ways to manage this condition and we believe that the medicine is very poor value for money. The HSE should consider not providing this medicine unless it can agree a suitable price reduction with the pharmaceutical company.

Next steps

When the HSE receives our recommendation, it will look at all the relevant data about zanubrutinib. The HSE makes the final decision on reimbursement.

Where can I get more information?

You can get more information about zanubrutinib from the following online options:

- the NCPE Technical Summary Document
- Brukinsa European Public Assessment Report (EPAR) - Medicine Overview
- searching for zanubrutinib on our website (www.ncpe.ie);
- searching for zanubrutinib on the European Medicines Agency (EMA) website (www.ema.europa.eu).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine.